{"prompt": "['Novartis', 'Confidential', 'Page 4', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '43', '9', 'Study discontinuation and completion', '44', '9.1', 'Discontinuation', '44', '9.1.1', 'Discontinuation of study treatment', '44', '9.1.2', 'Withdrawal of informed consent', '46', '9.1.3', 'Lost to follow-up', '46', '9.1.4', 'Early study termination by the sponsor', '46', '9.2', 'Study completion and post-study treatment', '47', '10 Safety monitoring and reporting', '47', '10.1 Definition of adverse events and reporting requirements', '47', '10.1.1', 'Adverse events', '47', '10.1.2', 'Serious adverse events', '49', '10.1.3', 'SAE reporting', '50', '10.1.4', 'Pregnancy reporting', '50', '10.1.5', 'Reporting of study treatment errors including misuse/abuse', '50', '10.2', 'Additional Safety Monitoring', '51', '10.2.1', 'Liver safety monitoring', '51', '10.2.2', 'Renal safety monitoring', '52', '11 Data Collection and Database management', '52', '11.1', 'Data collection', '52', '11.2', 'Database management and quality control', '53', '11.3', 'Site monitoring', '53', '12 Data analysis and statistical methods', '54', '12.1', 'Analysis sets', '54', '12.2', 'Subject demographics and other baseline characteristics', '55', '12.3 Treatments', '55', '12.4', 'Analysis of the primary endpoint(s)', '55', '12.4.1', 'Definition of primary endpoint(s)', '56', '12.4.2', 'Statistical model, hypothesis, and method of analysis', '56', '12.4.3', 'Handling of missing values/censoring/discontinuations', '57', '12.4.4', 'Sensitivity and Supportive analyses', '57', '12.5', 'Analysis of secondary endpoints', '58', '12.5.1', 'Safety Variables', '59']['Novartis', 'Confidential', 'Page 5', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '60', '12.7', 'Interim analyses', '60', '12.8', 'Sample size calculation', '61', '12.8.1', 'Primary endpoint(s)', '61', '13 Ethical considerations and administrative procedures', '61', '13.1', 'Regulatory and ethical compliance', '61', '13.2', 'Responsibilities of the investigator and IRB/IEC', '61', '13.3', 'Publication of study protocol and results', '62', '13.4', 'Quality Control and Quality Assurance', '62', '14 Protocol adherence', '62', '14.1', 'Protocol Amendments', '63', '15 References', '64', '16 Appendices', '66', '16.1', 'Appendix 1: Clinically notable laboratory values and vital signs', '66', '16.2', 'Appendix 2: Liver event and Laboratory trigger Definitions and Follow-up', 'Requirements', '67', '16.3', 'Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow-up', '69', '16.4', 'Appendix 4: Nasal Congestion Score Questionnaire', '70', '16.5', 'Appendix 5: SNOT-22 Questionnaire', '71', '16.6', 'Appendix 6: ACQ-5 Questionnaire', '72', '16.7', 'Appendix 7: Nasal Endoscopy', '74', 'List of tables', 'Table 1-1', 'Nasal Polyp Scale', '18', 'Table 2-1', 'Objectives and related endpoints', '19', 'Table 6-1', 'Medications allowed under certain conditions', '29', 'Table 6-2', 'Prohibited Medication', '30', 'Table 6-3', 'Blinding and unblinding plan', '32', 'Table 8-1', 'Assessment Schedule', '37', 'Table 8-2', 'Nasal Polyp Scale', '40', 'Table 8-3', 'Physical Assessments', '41', 'Table 8-4', 'Laboratory Assessments', '42', 'Table 10-1', 'Guidance for capturing the study treatment errors including', 'misuse/abuse', '51']\n\n###\n\n", "completion": "END"}